Direktorat Registrasi ObatValid

CEFOTAXIME SODIUM

BPOM Number: GKL1718829044A1
Approved: 31 March 2026
Expiry: 9 May 2028
Form: SERBUK INJEKSI

About This Registration

CEFOTAXIME SODIUM is a BPOM-registered direktorat registrasi obat in Indonesia, registered under number GKL1718829044A1. Its current registration status is Valid, with the licence valid until 9 May 2028. The product is registered to OTTO PHARMACEUTICAL INDUSTRIES - INDONESIA. BPOM first approved this registration in March 2026. All registration data is sourced directly from the official BPOM public database and updated daily.

Registration data updated by BPOM

This product's registration details were changed on 13 November 2025. This may reflect a status change, renewal, or correction by BPOM.

Registration Details

Application: newaero
Packaging: DUS, 10 VIAL @ 1 G
Department: Direktorat Registrasi Obat
Data Last Updated: 13 November 2025

Retail Audit Service

Get detailed market intelligence for this product across Indonesian retail channels

Multiple cities available

Custom questionnaires

Professional shoppers

Detailed reporting

Starting from $50 per city

What's included in the audit service?

Stock availability and positioning verification

Price checking and competitor analysis

Display quality and promotional material assessment

Store condition and customer experience evaluation

Custom questions tailored to your research needs

Professional photographs and detailed reports

Registered Owners

OTTO PHARMACEUTICAL INDUSTRIES - INDONESIA
KAB. BANDUNG BARAT
NPWP: 011047750441000
owner
View profile →

Manufacturing Sites

OTTO PHARMACEUTICAL INDUSTRIES - INDONESIA
KAB. BANDUNG BARAT
primary
View profile →

Ingredients (1)

CEFOTAXIME SODIUM

Market Intelligence

Owner Portfolio: OTTO PHARMACEUTICAL INDUSTRIES - INDONESIA holds 193 BPOM registrations
Manufacturer Scale: OTTO PHARMACEUTICAL INDUSTRIES - INDONESIA produces 193 registered products
Registration Age: Registered for 4 months

FDA Cross-Reference

via openFDA

Generic Name: CEFOTAXIME INJECTION
Product Type: HUMAN PRESCRIPTION DRUG
Route of Administration: INTRAMUSCULAR

Data sourced from the U.S. FDA drug label database (openFDA). May not exactly match this product variant.

Is this your product?